Literature DB >> 19736267

Psychotropic drug use during breastfeeding: a review of the evidence.

Filomena Fortinguerra1, Antonio Clavenna, Maurizio Bonati.   

Abstract

OBJECTIVE: The objective of this study was to review the existing literature on the use of various classes of psychotropic medications during breastfeeding to provide information about infant exposure levels and reported adverse events in breastfed infants.
METHODS: A bibliographic search in the Medline (1967 through July 2008), Embase (1975 through July 2008), and PsycINFO (1967 through July 2008) databases was conducted for studies on breastfeeding and psychotropic medications for a total of 96 drugs. References of retrieved articles, reference books, and dedicated Web sites were also checked. The manufacturers were contacted for drugs without published information. Original articles and review articles that provide pharmacokinetic data on drug excretion in breast milk and infant safety data were considered, to estimate the "compatibility level" of each drug with breastfeeding.
RESULTS: A total of 183 original articles were eligible for analysis. Documentation was retrieved for 62 (65%) drugs. In all, 19 (31%) psychotropic drugs can be used during lactation according to an evidence-based approach. For 28 drugs, the available data do not permit an evaluation of the drug's safety profile during breastfeeding and, for an additional 15 drugs, the exposure dose or observed adverse effects make their use unsafe.
CONCLUSIONS: Although most drugs are considered safe during breastfeeding, compatibility with breastfeeding has not been established for all psychotropic drugs. There is a need for additional research and accumulation of experience to guarantee a more rational use of psychotropic drugs during breastfeeding.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19736267     DOI: 10.1542/peds.2009-0326

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

Review 1.  The quality of lactation studies including antipsychotics.

Authors:  Hazel Hummels; Daphne Bertholee; Douwe van der Meer; Jan Pieter Smit; Bob Wilffert; Peter Ter Horst
Journal:  Eur J Clin Pharmacol       Date:  2016-08-24       Impact factor: 2.953

2.  A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.

Authors:  C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes
Journal:  CNS Drugs       Date:  2022-06-27       Impact factor: 6.497

Review 3.  Course of Illness and Treatment Updates for Bipolar Disorder in the Perinatal Period.

Authors:  Melissa M Batt; Aviva K Olsavsky; Shaleah Dardar; Celeste St John-Larkin; Rachel L Johnson; Mary D Sammel
Journal:  Curr Psychiatry Rep       Date:  2022-02-15       Impact factor: 8.081

Review 4.  Psychiatric consultation to the postpartum mother.

Authors:  Eleanor A Anderson; Deborah R Kim
Journal:  Curr Psychiatry Rep       Date:  2015-04       Impact factor: 5.285

Review 5.  Psychoactive drug exposure during breastfeeding: a critical need for preclinical behavioral testing.

Authors:  Irving Zucker
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

Review 6.  Concise review for physicians and other clinicians: postpartum depression.

Authors:  William V Bobo; Barbara P Yawn
Journal:  Mayo Clin Proc       Date:  2014-06       Impact factor: 7.616

7.  Treatment of postpartum depression: clinical, psychological and pharmacological options.

Authors:  Elizabeth Fitelson; Sarah Kim; Allison Scott Baker; Kristin Leight
Journal:  Int J Womens Health       Date:  2010-12-30

8.  Agomelatine for postpartum depression and breastfeeding.

Authors:  Le Xiao
Journal:  Ther Adv Psychopharmacol       Date:  2021-06-03

9.  Postpartum depression: psychoneuroimmunological underpinnings and treatment.

Authors:  George Anderson; Michael Maes
Journal:  Neuropsychiatr Dis Treat       Date:  2013-02-21       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.